Logicbio Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
65 Hayden Ave Fl 2, Lexington, Massachus...Phone Number
(617) 245-0399Website
www.logicbio.comRevenue
$7.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
1
1
1
1
About Logicbio Therapeutics
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The company's gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues.Explore more
Logicbio Therapeutics Org Chart
BA
Recruiting Coordinator
CW
Upstream Engineer II
AB
Scientist
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Logicbio Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Logicbio Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Logicbio Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Logicbio Therapeutics
Product Launch: Get notified when Logicbio Therapeutics launches new products
Check if Logicbio Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Logicbio Therapeutics recently announced quarterly report
Logicbio Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Logicbio Therapeutics is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Logicbio Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Logicbio Therapeutics
Compare insights from companies similar to Logicbio Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$10.8M
51-200
Private
-
1997
AY
Amy YokoyamaAssistant Director, UC Davis Mouse Biology Program Repository & Project Management
Company Profile Activity
Activity Insights
Logicbio Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Logicbio Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Logicbio Therapeutics.
Logicbio Therapeutics financials insights
Gather financial insights about Logicbio Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series B
$45M
2020
Stock Offering
$42M
Logicbio Therapeutics Tech Stack
A closer look at the technologies used by Logicbio Therapeutics
Most Recent Scoops
Left Company
Executive Move
Mergers & Acquisitions (M&A)
Left Company
Executive Move
As previously announced, Cecilia Jones, Chief Financial Officer, has left the company.
Left Company
Executive Move
Logicbio Therapeutics has announced that Cecilia Jones, Chief Financial Officer, will be leaving the organization, effective on September 23, 2022.
Left Company
Executive Move
Logicbio Therapeutics News & Media
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
- Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with prevention of severe weight loss and mortality when challenged with a high protein diet - Definitive merger agreement with Alexion,...BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) ForgeRock, Inc. (NYSE - FORG), SeaSpine Holdings Corporation (Nasdaq - SPNE), LogicBio Therapeutics, Inc. (Nasdaq – LOGC), Coffee Holding Co., Inc. (Nasdaq – JVA)
BALA CYNWYD, Pa., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.SHAREHOLDER ALERT: Weiss Law Reminds LOGC, POSH, AERC, and BTRS Shareholders About Its Ongoing Investigations
NEW YORK, Oct. 14, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor New...INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGC
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Logicbio Therapeutics
Sign Up For FreeTo access detailed company insights
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading... Read More
